Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06338150
Other study ID # STUDY-23-00503
Secondary ID GCO 19-01755R01C
Status Not yet recruiting
Phase
First received
Last updated
Start date June 2024
Est. completion date June 2026

Study information

Verified date March 2024
Source Icahn School of Medicine at Mount Sinai
Contact Cesar Rodriguez Valdes, MD, PhD
Phone (212) 241-7873
Email Cesar.Rodriguez@mssm.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This will be a 2 year study to evaluate and improve cancer sequencing as applied to the characterization of tumor molecular make-up and the identification of novel therapeutics (n=100). Participants who will undergo tumor biopsy for management of multiple myeloma (MM) will self-refer to the study or be referred by their treating physician. Participants will initially meet with a clinician to review study consents and provide medical, medication, and family history information. After informed consent, biospecimen samples from peripheral blood, cheek swab, and tumor samples from bone marrow (aspirate and biopsy), peripheral blood, or any mass/fluid containing tumor cells will be obtained (from procedures indicated as part of their standard oncology care) for cancer sequencing (CS) (whole exome sequencing of germline and tumor genomes, RNA sequencing of tumor transcriptome, single cell, and CyTOF analysis). CS data will be interpreted via somatic variation identification, network modeling, and cancer transcriptome profiling to facilitate mapping activity levels of genes to networks and for identifying genes activated or dysregulated in cancer cells. Sequencing and analysis will be performed at the Genomics Core Facility at the Icahn School of Medicine at Mount Sinai. In instances where internal sequencing capabilities do not allow for certain types of analysis, de-identified samples or data may be sent out to third parties for additional analysis. The study will be using GenPath, a division of BioReference® Health, LLC for this project which is a CLIA certified lab. All genetic tests will be performed in a CLIA certified lab and all tests will be FDA or NYS approved. The RNA Sequencing test will receive NYS Department of Health (Wadsworth Center) approval before results are provided to physicians and patients. Samples will be de-identified and processed by the Mount Sinai Human Immune Monitoring Core (HIMC) before being sent to an external CLIA-certified lab for sequencing and analysis. Interpretation will be performed by a multidisciplinary team that includes genomicists, pathologists, and clinicians familiar with the particular cancer diagnosed in the participant. Once results are available, they will be shared with the participant and treating physician during a follow-up results session and any findings obtained explained. This study is not intended to implement findings, only to report them.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must be 18 years of age at the time of registration. - Participant must have an established diagnosis of relapsed Multiple Myeloma based on IMWG criteria, be willing to participate, and able to consent - Participant must have a treating physician who agrees to participate in the study - Participant will be undergoing a bone marrow biopsy or tumor biopsy as part of their standard of care. - Patients must be willing to participate in this study and able to sign informed consent. - Participants are not participating in any interventional clinical trial using systemic therapy directed towards control of MM. Exclusion Criteria - Known diagnosis of AL amyloidosis, Waldenstrom Macroglobulinemia, POEMS, or CastlemanĀ“s disease. - Diagnosis of cancer other than myeloma or skin cancer (squamous cell or basal cell) that is ongoing or treated within the last 2 years. - Tumor sample inadequate or unavailable for analysis (e.g., due to insufficient number of tumor cells). - Patient will not be receiving systemic MM-directed chemotherapy/immunotherapy in the following 2 months from the time tumor biopsy is performed.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Mount Sinai Health System New York New York

Sponsors (2)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total number of somatic Single-nucleotide variants (SNVs) per patient The number of genetic alterations found in the genome through genetic sequencing and comparison to the most common genetic sequence. A given variant may describe an alteration that is benign, pathogenic, or of unknown significance. End of study at 30 months
Secondary Total number of somatic insertions (INS) per patient Total number of somatic insertions (INS) per patient. The number of instances where nucleotides have been erroneously added to the genome, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Total number of somatic deletions (DEL) per patient The number of instances where nucleotides that have been erroneously omitted from the genome, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Number of SNVs per megabase of the MM genome The number of genetic alterations detected in MM tumor cells through sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Number of INS per megabase of the MM genome The number of instances where nucleotides have been erroneously added to the MM tumor genome, per length of DNA, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Number of DEL per megabase of the MM genome The number of instances where nucleotides that have been erroneously omitted from the MM tumor genome, per length of DNA, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Number of mutations per megabase among MM subgroups The number of genetic alterations detectable in >1 % or <1 % of the population, per length of DNA, among multiple myeloma (MM) subgroups, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Number of mutations per megabase among genomic regions for all MM and mutational subgroups The number of genetic alterations detectable in >1 % or <1 % of the population, per length of DNA, by genetic region (i.e., promoter, coding region, and termination sequence), for all MM and mutational subgroups, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Gene mutations identified The number and type of genetic alterations detectable in >1 % or <1 % of the population identified, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Chromosomal abnormalities identified . The numbers and types of chromosomal abnormalities identified, as determined by genetic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary Molecular signatures identified Number and type of sets of biomolecular features identified that could be useful in predicting the course of disease or response to therapeutic intervention among patients with MM and other cancers, as determined by sequencing, and gene set variation and targeted drug analysis. End of study at 30 months
Secondary Established Prognostic markers identified The number and type of established prognostic markers identified. Evaluation of biological characteristics known to be useful in predicting the course of disease or response to therapeutic intervention among patients with MM and other cancers, as determined by sequencing and comparison to databases of known prognostic markers. End of study at 30 months
Secondary Somatic variants identified as targets of FDA-approved drugs (pharmacogenomics variant data) The number and type of genetic alterations found in the genome that could be treated with FDA-approved therapies, as determined by sequencing and comparison to databases of known targets and associated FDA-approved drugs. End of study at 30 months
Secondary Network-informed key driver variants identified Number and type of mutations known to lead to cancer cell transformation, growth, and spread in the body, as determined by genetic sequencing and comparison to the most common genetic sequence, and to databases of known cancer driver mutations. These mutations will be categorized as follows: those that are known targets of FDA-approved drugs, those that may be targets of drugs under development that are not yet FDA-approved, and those that may serve as targets for novel therapies. End of study at 30 months
Secondary Transcriptome variations identified Number and type of transcriptome variations identified with potential for the development of novel therapeutics (cell-surface expressed proteins that appear amenable to vaccine development), as determined by sequencing, network modeling, and cancer transcriptome profiling. End of study at 30 months
Secondary Germline mutations identified in cancer predisposition genes Number and type of germline mutations identified in cancer predisposition genes, as determined by genomic sequencing and comparison to the most common genetic sequence. End of study at 30 months
Secondary FDA approved drugs available that block enzymes produced in those pathways identified The number and type of FDA-approved drugs available that block enzymes produced in those pathways identified by comparison of genomic and transcriptomic findings to databases of known FDA-approved drugs and associated targets. End of study at 30 months
Secondary Treatment recommended by computational pipeline based on patient's clinical and genetic A listing of recommended treatments as determined by sequencing, analysis of the tumor microenvironment, and computational analysis. End of study at 30 months
Secondary Germline whole exome sequencing profile The results of whole exome sequencing of the germline genome. End of study at 30 months
Secondary Tumor genome whole exome sequencing profile The results of whole exome sequencing of the tumor genome. End of study at 30 months
Secondary Tumor transcriptome profile The results of RNA sequencing of the tumor transcriptome. End of study at 30 months
Secondary Single-cell sequencing profile The results of single cell sequencing analysis. End of study at 30 months
Secondary Cytometric profile The results of the cytometry by time of flight (CyTOF) analysis. End of study at 30 months
Secondary Signaling Pathways associated Signaling Pathways associated with each gene mutation, chromosomal abnormality and molecular signature, i.e. aging, defective DNA repair, and apolipoprotein B editing complex (APOBEC)/activation-induced deaminase activity, identified in Aim 1, as determined by sequencing and computational analysis. End of study at 30 months
Secondary Enzymes associated with each signaling pathway identified Enzymes associated with each signaling pathway identified as determined by sequencing and computational analysis. End of study at 30 months
Secondary Improvement of cancer sequencing-guided treatment recommendations by machine learning Use of artificial intelligence computing to implement cancer sequencing-based recommended therapies and improve accuracy of treatment prediction, to allow better interpretation of cancer sequencing data and advancement of the development of personalized and precision cancer therapies. Improvement will be measured by tracking the precision and accuracy of machine learning and evaluating the resulting data using statistical analysis. End of study at 30 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1